| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National … M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 111 (12), 5446-5456, 2008 | 3903 | 2008 |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2173 | 2014 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1914 | 2014 |
| The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease RP Rother, L Bell, P Hillmen, MT Gladwin Jama 293 (13), 1653-1662, 2005 | 1822 | 2005 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1694 | 2015 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1585 | 2018 |
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria P Hillmen, NS Young, J Schubert, RA Brodsky, G Socié, P Muus, A Röth, ... New England Journal of Medicine 355 (12), 1233-1243, 2006 | 1421 | 2006 |
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study MJ Keating, I Flinn, V Jain, JL Binet, P Hillmen, J Byrd, M Albitar, ... Blood, The Journal of the American Society of Hematology 99 (10), 3554-3561, 2002 | 1232 | 2002 |
| Natural history of paroxysmal nocturnal hemoglobinuria P Hillmen, SM Lewis, M Bessler, L Luzzatto, JV Dacie New England Journal of Medicine 333 (19), 1253-1258, 1995 | 1119 | 1995 |
| Diagnosis and management of paroxysmal nocturnal hemoglobinuria C Parker, M Omine, S Richards, J Nishimura, M Bessler, R Ware, ... Blood 106 (12), 3699-3709, 2005 | 1086 | 2005 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 991 | 2016 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 937 | 2018 |
| Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial D Catovsky, S Richards, E Matutes, D Oscier, MJS Dyer, RF Bezares, ... The Lancet 370 (9583), 230-239, 2007 | 927 | 2007 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 885 | 2021 |
| Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria P Hillmen, C Hall, JCW Marsh, M Elebute, MP Bombara, BE Petro, ... New England Journal of Medicine 350 (6), 552-559, 2004 | 876 | 2004 |
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ... Journal of Clinical Oncology 28 (10), 1749, 2010 | 785 | 2010 |
| Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia AC Rawstron, FL Bennett, SJM O'Connor, M Kwok, JAL Fenton, ... New England Journal of Medicine 359 (6), 575-583, 2008 | 783 | 2008 |
| Guidelines for the diagnosis and management of adult aplastic anaemia SB Killick, N Bown, J Cavenagh, I Dokal, T Foukaneli, A Hill, P Hillmen, ... British journal of haematology 172 (2), 187-207, 2016 | 748 | 2016 |
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia P Hillmen, AB Skotnicki, T Robak, B Jaksic, A Dmoszynska, J Wu, ... Journal of Clinical Oncology 25 (35), 5616-5623, 2007 | 736 | 2007 |
| Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria P Hillmen, P Muus, U Dührsen, AM Risitano, J Schubert, L Luzzatto, ... Blood, The Journal of the American Society of Hematology 110 (12), 4123-4128, 2007 | 708 | 2007 |
